Lei Yu, Wang Qian, Wang Feixiang, Mu Guo
Department of Anesthesiology, Guangyuan Central Hospital, Guangyuan, 628000, Sichuan, China.
Department of Anesthesiology, The Affiliated Hospital, Southwest Medical University, Luzhou, 646000, China.
Mol Biol Rep. 2025 Sep 11;52(1):891. doi: 10.1007/s11033-025-11019-8.
Chronic pain has emerged as a disorder of persistent neuroimmune dysregulation, with microglia playing a pivotal role in shaping maladaptive plasticity. Beyond classical inflammatory pathways, recent discoveries highlight microglial involvement in epigenetic remodeling, metabolic reprogramming, and synaptic modulation. These multidimensional processes sustain microglial activation and promote central sensitization, even in the absence of ongoing peripheral injury. This review proposes a comprehensive framework for understanding microglial regulation in chronic pain, emphasizing the failure of immune tolerance, aberrant neuron-glia signaling, and the emergence of disease-perpetuating microglial states. We further discuss therapeutic strategies aimed at selectively targeting microglial phenotypes, including HDAC inhibitors, metabolic modulators, and pathway-specific antagonists. By integrating mechanistic depth with translational insights, this review reframes microglia not only as inflammatory mediators, but as dynamic regulators whose dysregulation underlies pain chronification.
慢性疼痛已成为一种持续性神经免疫失调的病症,其中小胶质细胞在塑造适应不良的可塑性方面起着关键作用。除了经典的炎症途径外,最近的发现突出了小胶质细胞参与表观遗传重塑、代谢重编程和突触调节。即使在没有持续外周损伤的情况下,这些多维度过程也会维持小胶质细胞的激活并促进中枢敏化。本综述提出了一个全面的框架来理解慢性疼痛中的小胶质细胞调节,强调免疫耐受的失败、异常的神经元-胶质细胞信号传导以及导致疾病持续的小胶质细胞状态的出现。我们进一步讨论了旨在选择性靶向小胶质细胞表型的治疗策略,包括组蛋白去乙酰化酶抑制剂、代谢调节剂和途径特异性拮抗剂。通过将机制深度与转化见解相结合,本综述不仅将小胶质细胞重新定义为炎症介质,而且将其视为动态调节因子,其失调是疼痛慢性化的基础。